ArticleClinical kidney journal2026
Serum T50 is not independently associated with coronary artery calcification in early chronic kidney disease.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The serum T50 test quantifies calcification propensity, with lower values indicating a higher propensity for calcification. Lower T50 values have been associated with adverse cardiovascular outcomes, particularly in advanced chronic kidney disease. Whether serum T50 is associated with coronary artery calcification (CAC) in individuals with mildly to moderately reduced kidney function remains unclear. We examined this association in a population-based cross-sectional study. Methods: We analysed 1945 participants from the population-based Lifelines ImaLife cohort with mildly to moderately reduced kidney function (estimated glomerular filtration rate, 37.5-87.6 ml/min/1.73 m²). Serum T50 was measured using a standardized nephelometric assay. CAC was assessed by electrocardiographically triggered non-contrast computed tomography and categorized into 0, 1-99, 100-399, and ≥400 Agatston units. Associations between continuous T50 (per 10-min increase) and CAC categories were examined using multinomial logistic regression. Results: Of the 1945 participants, 56.5% had detectable CAC (CAC 1-99: 30.9%, 100-399: 14.4%, ≥400: 11.2%). In crude analyses, higher T50 values were associated with the presence of CAC [odds ratio (OR) 1.02, 95% confidence interval 1.01-1.03] and with CAC categories 1-99, 100-399, and ≥400 versus 0 (ORs 1.01, 1.02, and 1.03, respectively). These associations were no longer significant after adjustment for age, body mass index, and sex. Subgroup analyses did not identify risk groups in which T50 was significantly associated with the presence or severity of CAC. Conclusion: In this cohort with mildly to moderately reduced kidney function, T50 was not independently associated with prevalent CAC after multi-variable adjustment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.